NCT01531959View on ClinicalTrials.gov

Midodrine for the Treatment of Refractory Hypotension

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
HypotensionCritical Illness
Interventions
DRUG

Midodrine

Patients will be randomized to blinded to 20 mg of midodrine

DRUG

Placebo

Patients will be randomized to blinded placebo control

Trial Locations (3)

60009

Sir Charles Gairdner Hospital, Nedlands

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Sir Charles Gairdner Hospital

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01531959 - Midodrine for the Treatment of Refractory Hypotension | Biotech Hunter | Biotech Hunter